The impact on patients quality of life can be profound.[13] The efficacy of osimertinib in NSCLC patients with bone metastases remains controversial.[9] The cases in this report remind us that osimertinib may be a promising clinical option for patients with EGFR 19del mutation with lung cancer with bone metastases, and future prospective studies with large sample sizes are needed to further validate the efficacy of osimertinib in patients with bone metastases from NSCLC. Here, EGFR is linked to lung cancer.